NCT01977456View on ClinicalTrials.gov

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

April 30, 2015

Conditions
StrokeBrain Infarction
Interventions
DRUG

Eptifibatide

IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.

Trial Locations (8)

41017

St. Elizabeth Healthcare System Edgewood, Edgewood

41042

St. Elizabeth Healthcare Florence, Florence

41075

St. Elizabeth Healthcare Ft. Thomas, Fort Thomas

45219

The Christ Hospital, Cincinnati

University of Cincinnati Medical Center, Cincinnati

45220

Good Samaritan Hospital, Cincinnati

45236

Jewish Hospital, Cincinnati

45242

Bethesda North Hospital, Cincinnati

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Arthur Pancioli

OTHER

NCT01977456 - Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR) | Biotech Hunter | Biotech Hunter